Low-frequency whole-body vibration technology developed by Finnish company Neurosonic was used in a study led by the University of Oulu and Oulu University Hospital (OYS). The study was published in Nature Communications on 3 November 2026. It investigated whether the movement of brain fluids and the transfer of proteins from the brain into the bloodstream could be enhanced by combining vibration with a vasodilating medicine.

This media kit contains background material for journalists:

• Press release in Finnish and English
• White paper on the study
• About Neurosonic
• Images of the Mobile Mattress
• Neurosonic logos

All materials are free to use for editorial purposes. Please credit images to Neurosonic.

For interview requests about Neurosonic and its technology:

Juha Suoniemi, CEO
juha.suoniemi@neurosonic.fi